Harold J. Burstein, MD, PhD, discusses the management of adverse events in patients with HER2+ breast cancer, and the Oncology Brothers provide closing thoughts on the entire discussion.
Bria-IMT Regimen Exceeds Survival Data of SOC in Metastatic Breast Cancer
Four of 13 patients with metastatic breast cancer recruited in 2022 for the phase 2 clinical study evaluating Bria-IMT remain in survival follow-up.
Applying Updated Breast Cancer Findings From ASCO to Clinical Practice
Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.
Ultra-Hypofractionated RT Shows Control, Tolerability in Elderly Breast Cancer
Bin Gui, MD, discussed how ultra-hypofractionated radiotherapy may be a convenient treatment option for elderly patients with early breast cancer.
Finding a Place for Exercise Oncology in the Treatment of Breast Cancer
Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.
Gene Expression Test May Predict Added Atezolizumab Benefit in TNBC
Phase 2 data indicate that the use of DetermaIO was predictive of a pathologic complete response with the addition of immunotherapy to chemotherapy in TNBC.
Elacestrant Combo Shows Activity, Tolerability in Metastatic Breast Cancer
Investigators report no grade 4 adverse effects among patients who received elacestrant/abemaciclib in the phase 1b/2 ELECTRA trial.